Pierre-Henri Benhamou co-founded DBV in 2002, and today serves as the Company’s Chairman and Chief Executive Officer. In collaboration with Dr. Christophe Dupont and Bertrand Dupont, Dr. Benhamou led the development and patenting of EPIT®, or epicutaneous immunotherapy. Prior to co-founding DBV, Dr. Benhamou was a physician in pediatric gastroenterology. He received an M.D. from Faculté de Médecine de Paris in 1984 and his specialization degree in Pediatrics in 1987. A recognized thought leader in areas of science and innovation, Dr. Benhamou has authored numerous publications in the fields of food allergies and immunotherapy. In 2003, he received the Altran Foundation Prize for Innovation.